Hepatobiliary Tumors Tissue Samples Acquisition

Peking Union Medical College Hospital450 enrolled

Overview

Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, so it is of great significance to find important prognostic markers and then screen out specific subgroups of people; meanwhile, chronic hepatitis, cirrhosis, and healthy control participants also need to show the evolution of tumors and discover specific diagnostic markers as a control group. Moreover, targeted therapy and immunotherapy make cancer treatment enter a new field, but only part of patients achieve response rates and reach clinical benefit. However, these drugs are expensive and can cause treatment-related adverse events. Therefore, reliable biomarkers identification is needed to help predict the response to these treatment options in order to screen patients with better responsiveness and avoid wasting money. Multi-omics research can reveal the characteristics of hepatobiliary tumors more deeply and find meaningful therapeutic targets. Therefore, 450 patients at least 18 years of age with hepatobiliary tumors were included in this study.

OBJECTIVES: 1. Observe the biomarkers of resectable hepatobiliary tumor recurrence (DFS) and survival (OS); 2. Observe the evolution of tumors and discover specific diagnostic markers as a control group. 3. Observe the response (ORR), progression (PFS) and survival (OS) biomarkers of targeted immunotherapy for advanced hepatobiliary tumors; 4. To elaborate on the multi-omics study of hepatobiliary tumors, to further subtype and find therapeutic targets

Study Type

OBSERVATIONAL

Enrollment

450

Conditions

Hepatocellular Carcinoma Cholangiocarcinoma Gallbladder Cancer

Interventions

Gene expression analysisOTHER

Gene expression analysis

Genomic analysisOTHER

Genomic analysis

Protein expression analysisOTHER

Protein expression analysis

Proteomic profilingOTHER

Proteomic profiling

Polymerase chain reactionOTHER

Polymerase chain reaction

Mass spectrometryOTHER

Mass spectrometry

ImmunohistochemistryOTHER

Immunohistochemistry

Metabolomics profilingOTHER

Metabolomics profiling

Methylation and epigenetic analysisOTHER

Methylation and epigenetic analysis

Liquid biopsy analysisOTHER

Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis

Laboratory biomarker analysisOTHER

Laboratory biomarker analysis (such as AFP, CA19-9, CEA)

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Be older than 18 years old; 2. ECOG 0-2 points; 3. May have received treatment; 4. Clinical consideration or diagnosis of benign and malignant hepatobiliary tumors; or chronic hepatitis, cirrhosis, or healthy control participants; 5. Patients may have received or are about to undergo surgery, chemotherapy, radiotherapy, targeted therapy, local therapy, immunotherapy, etc.; 6. Patients understand and are willing to sign written informed consent documents. Exclusion Criteria: 1. The doctor thinks it is not suitable to enter the group (mental disorder or poor compliance, etc.) 2. Pregnant women; 3. Active or uncontrollable infections (fungi, bacteria, etc.); 4. Estimated survival time \<12 weeks; 5. If the patient is receiving chronic anticoagulant therapy, the anticoagulant withdrawal should not be shorter than 3 days; 6. In the evaluation of the doctor, there is a risk of uncontrolled complications in the biopsy.

Outcomes

Primary Outcomes

Collected samples

Collected normal tissue, tumor samples, blood, urine, feces, ascites, bile samples from patients with hepatobiliary cancers